OUR TEAM
Board of Directors
Chairman of the Board
Ian is a Professor of Medicine and Vice Chancellor’s Professorial Fellow at Monash University a Non-executive director serving on the boards of several US and Australian Healthcare and life science companies. Currently he also serves on the Boards of Breakthrough Victoria, MTPConnect and WesternHealth Victoria.
Until mid 2023, he served as the Executive Vice President and Global Chief Medical Officer at Boston Scientific focusing on a vision of transformative clinical science and innovative care for all patients with chronic non-communicable diseases through his critical input into the company’s global clinical strategy and new business development plan.
Prior to Boston Scientific in 2017, Ian was Professor & Director of MonashHeart, the internationally recognized cardiovascular service within Monash Health and Monash University, a position he held for 12 years.
For more than 30 years as a practicing physician, clinical trialist and interventional cardiologist, he mentored and fostered the career of a generation of academic and clinical cardiologists and performed more than 20,000 invasive cardiac and coronary procedures. He was the chief investigator or a principal investigator of many major international, multi-center, randomized trials including many world-first-in-human studies. He has published more than 500 peer-reviewed scientific manuscripts, delivered more than 500 invited lectures internationally and nationally.
In 2012 Ian received an Order of Australia (AM) in the General Division for outstanding service to medicine in the field of Cardiology as a clinician and researcher and for advisory roles with a range of public health and organizations. In 2019 he received a Doctor of Laws, Honoris Causa for outstanding service to Monash University.
Board Member
Kelly Constable, is a commercialization expert with over 20 years’ experience in the US and Europe at global biotech firms, leading global launch strategies for multiple billion dollars therapeutics. She has led deals with multinationals and raised equity from venture and multinationals. Since landing in Australia 7 years ago, her portfolio has closed ~ A$200M in financing, had two successful turnarounds and one exit. She has served as a CEO and other executive management roles, has negotiated with or represented major research institutes, served as Executive Chair of a venture backed startup, as Board Member, and is currently a Senior Advisor to Lumira Ventures, an international investment firm with intent to establish in Australia.
Kelly learned sales and marketing at Abbott. Kelly then joined Amgen in 2006, a world leader in biotechnology. She led the launch of the Sureclick autoinjector in 2006, relaunched Aranesp, and led the US launch strategy for Prolia in osteoporosis in 2009, each >$1B annual sales products. Kelly also led the global launch strategy for migraine through 2016.
Kelly developed her expertise in precision medicine when she was asked to create a US innovation unit. In this role, she led and negotiated Amgen’s first technical alliance with GE Healthcare and developed and launched the first point of care software algorithm deployed initially in the US and now globally. Next Kelly co-founded Amgen’s first precision oncology initiative as a start-up inside Amgen, developing a novel algorithm in cancer, raising $20M of seed funding and managing Amgen’s first commercial software team with 50 cross-discipline experts in mathematics, software, regulatory, operations, and commercialization. She oversaw the development and implementation of Amgen’s first software medical device solution in Germany.
Steffen Hovard is a globally recognized MedTech leader and Board Professional with over 25 years of experience driving high-stakes value creation across the U.S., Europe and Asia. He leverages experiences from two decades at Coloplast to lead early-stage companies through the critical transitions from clinical-stage development to regulatory approval and commercialization.
His strategic and operational background in urology/urogynecology is rooted in his tenure as President of Coloplast Interventional Urology, where he scaled the business to $300M in revenue and a valuation exceeding $1B. Most recently he was CEO and Board Director for Neuspera Medical, where he steered the company through the pivotal trial for an implantable sacral neuromodulation device for treatment of Overactive Bladder (OAB), secured a $23M capital raise with a new strategic investor, and led the submission of its PMA.
Mr. Hovard serves on several boards for innovative MedTech firms, where he focuses on building the infrastructure and organizational readiness required to scale following regulatory milestones. In addition to his board roles, he acts as an Executive Advisor to Venture Capital and Private Equity firms. He holds an MSc from Copenhagen Business School.